lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio 
Welcome,         Profile    Billing    Logout  
 0 Diseases   4 Trials   4 Trials   17 News 


12»
  • ||||||||||  Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML (Halls G-H (San Diego Convention Center)) -  Nov 3, 2023 - Abstract #ASH2023ASH_6504;    
    P1b/2
    Entospletinib (ENTO) and lanraplenib (LANRA) are inhibitors of spleen tyrosine kinase (SYK); the latter is a next-generation SYK inhibitor and is currently being evaluated in combination with gilteritinib (GILT) in patients with relapsed or refractory FLT3-mutated AML (NCT05028751)...Two different AML patient cohorts were assessed by ex vivo treatment with ENTO, LANRA and combinations of LANRA (trametinib, gilteritinib (GILT), aPD-1) over a range of time points (2h, 4h, 3d and 9d) and readouts for cellular phenotype (e.g., differentiation state, immune cell populations) and functional readouts (pSYK, viability) for each cohort were analyzed by HP-FC and sc-MI and associated with available mutation information (bulk gene and single cell RNA sequencing)...These support studies investigating the use of pSYK inhibitors in combination with other therapies to reduce tumor burden, and as an improved line of treatment for AML. Acknowledgements: We are appreciative of the patients and families for their time and participation.
  • ||||||||||  entospletinib (GS-9973) / Kronos Bio
    Responses in patients with AML and treated with entospletinib monotherapy. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_6110;    
    P1b/2
    We are testing Lanraplenib, a next-generation SYK inhibitor with enhanced selectivity, and more favorable pharmacologic properties in combination in genetically defined subsets of AML (NCT05028751). Clinical trial information: NCT02343939.
  • ||||||||||  Immunohistological pattern-stratification opens the door for reliabletargeted treatment strategies in cutaneous lupus erythematosus (Ito Hall, University of Tokyo) -  Apr 13, 2023 - Abstract #ISID2023ISID_2364;    
    This study demonstrates that > 90% of CLE patients might be prone to betreated with at least one targeted drug, which were developed for the treatment of SLE oris in clinical studies for CLE. These drugs include belimumab (anti-Blys/ B cells) andanifrolumab (anti-IFNabR), which have already been approved for the treatment of SLEby FDA and EMA, but also anti-pDCs drugs (BIIB059 (anti-BDCA2); Daxdilimab (AntiILT7)) and inhibitors of the JAK/STAT pathway (Tofacitinib (JAK), Lanraplenib &Filgotinib (JAK/SYK), Deucravacitinib (TYK2), which block IFN-mediatedinflammatory pathways.
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, entospletinib (GS-9973) / Kronos Bio
    Influence of efflux and uptake transporters on the pharmacokinetics of the SYK inhibitors entospletinib and lanraplenib (Hall Bordeaux) -  Jan 31, 2023 - Abstract #ESMOTAT2023ESMO_TAT_190;    
    Conclusions ABC transporters play an important role in the brain disposition of entospletinib and lanraplenib, although they have only a slight impact on the plasma exposure of entospletinib. The role for the OATP uptake transporters seems to be less prominent for both drugs, but they might be involved in the tissue disposition of lanraplenib, but not of entospletinib.
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, entospletinib (GS-9973) / Kronos Bio
    Journal:  Neutrophil-specific Syk expression is crucial for skin disease in experimental epidermolysis bullosa acquisita. (Pubmed Central) -  Jan 15, 2023   
    Entospletinib and lanraplenib, two second generation, Syk-specific inhibitors effectively abrogated IC-induced responses of human neutrophils and decreased the anti-C7 antibody-initiated, neutrophil-mediated ex vivo dermal-epidermal separation in human skin samples. Taken together, these results point to a crucial role for Syk in neutrophils in the development and progression of epidermolysis bullosa acquisita and suggest Syk inhibition as a potential therapeutic strategy.
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, Tavalisse (fostamatinib) / Rigel, Kissei
    The impact of Syk-inhibition on 5B9 monoclonal HIT antibody-mediated procoagulant platelet formation (#229) (Harmony 2 (C2)) -  Jan 7, 2023 - Abstract #GTH2023GTH_175;    
    Taken together, these results point to a crucial role for Syk in neutrophils in the development and progression of epidermolysis bullosa acquisita and suggest Syk inhibition as a potential therapeutic strategy. Furthermore, experiments with the Syk inhibitors fostamatinib (R406) and lanraplenib revealed that the formation of procoagulant PLTs seems to be dependent on Syk mediated PLT activating signaling mechanisms, as preincubation of PLTs with these Syk inhibitors resulted in significant inhibition of Ab-induced procoagulant PLT formation (IC50: 14.35
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, entospletinib (GS-9973) / Kronos Bio
    Enhanced utility of AI/ML methods during lead optimization by inclusion of 3D ligand information (S401a (McCormick Place Convention Center)) -  Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_10241;    
    This includes an effort to retrospectively re-identify drug candidate molecules based on data from an intermediate stage of the project which illustrates the use of chemical space constraints and the application of evolutionary pressure within GTD. Additionally, a study of how the GTD system can blend features from alternate chemical series with the Gilead lead series shows some of the unique ways GTD applies AI/ML to drug discovery.
  • ||||||||||  SYK INHIBITION DRIVES DEEP RESPONSES IN A BIOMARKER GUIDED SUBSET OF AML ALONE AND IN RATIONAL COMBINATIONS () -  May 13, 2022 - Abstract #EHA2022EHA_741;    
    P1b/2, P3
    Finally, robust synergy across a range of LANRA concentrations was found when paired with venetoclax and gilteritinib...The highly predictive response for SYK inhibition with concurrent NPM1 m/ FLT3 -ITD mutations and synergy with gilteritinib observed in patient derived models is supportive of its clinical evaluation in combination with a FLT3 inhibitor. Our work supports the rationale for an ongoing Phase 1b/2 study of LANRA in combination with gilteritinib in patients with R/R FLT3 -mutated AML.
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, Xospata (gilteritinib) / Astellas, entospletinib (GS-9973) / Kronos Bio
    PHARMACOLOGICAL INHIBITION OF SYK CONFERS ANTI-PROLIFERATIVE AND NOVEL ANTI-TUMOR IMMUNE RESPONSES IN AML () -  May 13, 2022 - Abstract #EHA2022EHA_692;    
    P1/2, P1b/
    The selective, orally bioavailable SYK inhibitor entospletinib (ENTO) has demonstrated clinical activity and tolerability in HOXA9/MEIS1- driven AML...Lanraplenib (LANRA) is a next-generation SYK inhibitor with similar potency and selectivity to ENTO but with more favorable pharmacologic properties that is currently being evaluated in combination with gilteritinib in pts with relapsed or refractory FLT3 -mutated AML (NCT05028751)...Our studies illustrate that ENTO and LANRA may restore T-cell proliferation in a subset of AML pts with dysfunctional T-cell responses, suggesting a novel mechanism of action. Additional studies are required to fully understand the mechanism of SYK-mediated antitumor immune responses in AML.
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
    Journal:  Identification of CDK1 as a candidate marker in cutaneous squamous cell carcinoma by integrated bioinformatics analysis. (Pubmed Central) -  Feb 5, 2022   
    The GSE117247, GSE32979, and GSE98767 datasets comprising a total of 32 cSCC samples and 31 normal skin tissue samples were obtained from the National Center for Biotechnology Information Gene Expression Omnibus database...CDK1 is a gene closely related to the occurrence and development of cSCC, which may play an important role. Bioinformatics analysis shows that it is involved in the important pathway of the pathogenesis of cSCC, and may be recognized and applied as a new biomarker in the future diagnosis and treatment of cSCC.
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
    Trial completion, Enrollment change:  Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function (clinicaltrials.gov) -  Nov 8, 2018   
    P1,  N=35, Completed, 
    Recruiting --> Active, not recruiting | N=32 --> 9 Recruiting --> Completed | N=60 --> 35
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio, Velexbru (tirabrutinib) / Ono Pharma, Gilead, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
    Trial completion date, Trial primary completion date:  Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome (clinicaltrials.gov) -  Apr 26, 2018   
    P2,  N=140, Recruiting, 
    Trial completion date: Jul 2019 --> Jan 2020 | Trial primary completion date: Oct 2018 --> Mar 2019 Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Mar 2019
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
    Trial completion date, Trial primary completion date:  Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function (clinicaltrials.gov) -  Apr 5, 2018   
    P1,  N=60, Recruiting, 
    Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Mar 2019 Trial completion date: Jun 2018 --> Oct 2018 | Trial primary completion date: Jun 2018 --> Oct 2018
  • ||||||||||  lanraplenib (GS-9876) / Gilead, Galapagos, Kronos Bio
    Trial primary completion date:  Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function (clinicaltrials.gov) -  Nov 27, 2017   
    P1,  N=60, Recruiting, 
    Trial completion date: Jun 2018 --> Oct 2018 | Trial primary completion date: Jun 2018 --> Oct 2018 Trial primary completion date: Dec 2017 --> Jun 2018